Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study ID
NCT07076914
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Experimental (Health Canada Approved Proton Pump Inhibitors) — DRUG
    The intervention uses a proton pump inhibitor as a preventative measure

Study Details

A randomized controlled trial to assess the impact of prophylactic proton pump inhibitor use to improve esophagitis in lung cancer patients undergoing radiation. Patients will be randomized into a standard of care arm or the prophylactic proton pump (daily) arm.

Key Dates

First listed
Jul 22, 2025
Start date
Oct 2, 2025
Status verified
Jul 2025
Primary completion
Jan 2, 2028
Completion
Oct 2, 2032

Study Design

Enrollment
58 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Standard of Care
    Radiation delivered as per standard institutional approaches
  • Experimental: Prophylactic Proton Pump Inhibitor
    Daily use of pantoprazole magnesium, rabeprazole or lansoprazole

Primary Outcome Measure

Worst patient-reported esophageal pain score during radiation [ Time Frame: baseline last week of radiation post-treatment ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies